22 Jun 2021 | 03:00 PM GMT

D2C strategies for Digital Health companies

Participants:

Melinda Decker AdvisorPlexus Ventures
Melinda Decker
AdvisorPlexus Ventures
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Abhishek Shah Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Abhishek Shah
Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Conor Hayes Co-Founder Techvie SoftwareMunster Technological University
Conor Hayes
Co-Founder Techvie SoftwareMunster Technological University
Cyndi Williams SVP Strategic OperationsDojo
Cyndi Williams
SVP Strategic OperationsDojo
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Gaurav Dharmashaktu VP MarketingAuthBridge
Gaurav Dharmashaktu
VP MarketingAuthBridge
Hicham Naim VP, Head of Strategy & TransformationTakeda
Hicham Naim
VP, Head of Strategy & TransformationTakeda
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Kasparas Aleknavicius Medical AdvisorKilo.Health
Kasparas Aleknavicius
Medical AdvisorKilo.Health
Larisa Rashid Director of MarketingCognito Therapeutics, Inc.
Larisa Rashid
Director of MarketingCognito Therapeutics, Inc.
Laura Hamilton EVP of Business DevelopmentHealthBeacon
Laura Hamilton
EVP of Business DevelopmentHealthBeacon
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo

About this Meeting

Health-related Google searches are increasing year after year, showing that consumers are interested in knowing more about their health conditions and how to manage them. This might pose D2C as a reasonable market strategy for digital health companies. The fact that we have seen Digital Health companies shifting from the traditional pharma pathway towards D2C, also reveals the potential of this route to market, which can help to gain traction faster and make the business more scalable. Join this meeting where we will have an informal conversation on: 
 
-Therapeutic areas more suited to use D2C strategie
-There are companies that use D2C as an additional route to market to payers, employers, etc. What do these blended routes to market look like?